Filing Details
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) filed a Form 8-K with the Securities and Exchange Commission on July 20, 2026, disclosing a material event.
8k filedNASDAQ:FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Material Event to SEC
Filing Details 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) filed a Form 8-K with the Securities and Exchange Commission on July 20, 2026, disclosing a material event. Market…
Market Context
4D Molecular Therapeutics, Inc.'s stock currently trades at $11.09 with a market capitalization of $510.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for 4D Molecular Therapeutics, Inc.'s stock.
All SEC filings for 4D Molecular Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View FDMT Stock Page
Frequently Asked Questions
Where can I read FDMT's SEC filings?
Browse all filings on our FDMT SEC filings page.
What types of SEC filings does 4D Molecular Therapeutics, Inc. file?
Public companies like 4D Molecular Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.